Montravers F, Grahek D, Kerrou K, et al: Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? J Nucl Med 47: 1455-1462, 2006
Koukouraki S, Strauss LG, Georgoulias V, et al: Comparison of the pharmacokinetics of 68Ga-DOTAROC and (18F) FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 33: 1115-1122, 2006
Meisetschläger G, Poethko T, Stahl A, et al: Gluc-Lys ([18F] FP) -TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In] DTPA-octreotide. J Nucl Med 47: 566-573, 2006
Rogers BE, Parry JJ, Andrews R, et al: MicroPET imaging of gene transfer with a somatostatin receptor-based reporter gene and 94mTc-Demotate 1. J Nucl Med 46: 1889-1897, 2005
Breeman WA, de Jong M, de Blois E, et al: Radiolabelling DOTA-peptides with 68Ga. Eur J Nucl Med Mol Imaging 32: 478-485, 2005